Premium
Genetic prediction of myopia: prospects and challenges
Author(s) -
Guggenheim Jeremy A.,
Ghorbani Mojarrad Neema,
Williams Cathy,
Flitcroft D. Ian
Publication year - 2017
Publication title -
ophthalmic and physiological optics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.147
H-Index - 66
eISSN - 1475-1313
pISSN - 0275-5408
DOI - 10.1111/opo.12403
Subject(s) - orthokeratology , psychological intervention , medicine , intervention (counseling) , randomized controlled trial , optometry , intensive care medicine , medline , pediatrics , ophthalmology , surgery , nursing , cornea , political science , law
Appeals have been made for eye care professionals to start prescribing anti-myopia therapies as part of their routine management of myopic children.[1-3] These calls are fuelled by two key considerations. Firstly, that interventions to slow myopia progression have shown success in randomized controlled trials (RCTs)[4-7], and secondly, appreciation that the risk of sight-threatening complications rises dose-dependently with the level of myopia.[8, 9] Notwithstanding existing gaps in knowledge regarding the efficacy of current treatments (see below), these considerations argue that myopia control interventions should be widely adopted, and that they should be instigated at an early age – especially in children most at risk – in order to reduce the final level of myopia. Therefore in managing a child with myopia, an eye care professional would have to decide not only which therapy to recommend, but at what age to start treatment. In this review we discuss the future role of genetic prediction in helping clinicians treat myopia.